Advertisement
Screener

Freenome, Inc. (FRNM) Investing Cash Flow

1.3 / 5 stars · 2/8 Roast Me

Freenome, Inc. Investing Cash Flow

Freenome, Inc. (FRNM) reported Investing Cash Flow of $8.16 million for the 6-month period ending 2026-06-30, per its S-1 filed 2026-08-18.

Financial Statements › Cash Flow › Investing Activities

us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-18

  • Freenome, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $8.16M, a 2619.58% increase year-over-year.
  • Freenome, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
  • Freenome, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $0.00.
  • Freenome, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $0.00.
Period endNet Cash Provided by (Used in) Investing Activities 0 monthNet Cash Provided by (Used in) Investing Activities 3 monthNet Cash Provided by (Used in) Investing Activities 6 monthNet Cash Provided by (Used in) Investing Activities 9 monthNet Cash Provided by (Used in) Investing Activities 12 month
2026-06-30$8.16M
derived: S-1 6 month − S-4/A 3 month · filed 2026-08-18
$8.16M
S-1 · filed 2026-08-18
$8.16M
derived: sum of 3 quarters · filed 2026-08-18
$8.16M
derived: sum of 4 quarters · filed 2026-08-18
2026-03-31$0.00
S-4/A · filed 2026-06-11
$0.00
derived: sum of 2 quarters · filed 2026-08-18
$0.00
derived: sum of 3 quarters · filed 2026-08-18
$300.00K
derived: sum of 4 quarters · filed 2026-08-18
2025-12-31$0.00
derived: S-1 12 month − 10-Q 9 month · filed 2026-08-18
$0.00
derived: sum of 2 quarters · filed 2026-08-18
$300.00K
derived: sum of 3 quarters · filed 2026-08-18
$600.00K
S-1 · filed 2026-08-18
2025-09-30$0.00
derived: 10-Q 9 month − S-1 6 month · filed 2025-11-13
$300.00K
derived: sum of 2 quarters · filed 2026-08-18
$600.00K
10-Q · filed 2025-11-13
$600.00K
derived: sum of 4 quarters · filed 2026-08-18
2025-06-30$300.00K
derived: S-1 6 month − S-4/A 3 month · filed 2026-08-18
$600.00K
S-1 · filed 2026-08-18
$600.00K
derived: sum of 3 quarters · filed 2026-08-18
$600.00K
derived: sum of 4 quarters · filed 2026-08-18
2025-03-31$300.00K
S-4/A · filed 2026-06-11
$300.00K
derived: sum of 2 quarters · filed 2026-08-18
$300.00K
derived: sum of 3 quarters · filed 2026-08-18
-$85.95M
derived: sum of 4 quarters · filed 2026-08-18
2024-12-31$0.00
derived: S-1 9 month − 10-Q 6 month · filed 2026-08-18
$0.00
derived: sum of 2 quarters · filed 2026-08-18
-$86.25M
S-1 · filed 2026-08-18
2024-09-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-13
-$86.25M
10-Q · filed 2025-11-13
2024-06-30-$86.25M
10-Q · filed 2025-08-13
2024-03-31$0.00
10-Q · filed 2025-05-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
EXAGEN INC. (XGN)United States$0.212B-5.95
SERA PROGNOSTICS, INC. (SERA)United States$0.062B-5.75
AMERICAN SHARED HOSPITAL SERVICES (AMS)United States$0.010B-5.64
Advanced Biomed Inc. (ADVB)$0.009B
Aclarion, Inc. (ACON)United States$0.008B
BioNexus Gene Lab Corp (BGLC)$0.004B
BIODESIX INC (BDSX)United States$0.312B
Fulgent Genetics, Inc. (FLGT)United States$0.593B-6.70
Lumexa Imaging Holdings, Inc. (LMRI)United States$0.951B
CASTLE BIOSCIENCES INC (CSTL)United States$1.074B-37.45